Table 4.
Multivariate analyses of associations between unfavorable genotypes and the treatment response risk.
| Analysis | Unfavorable genotypes and clinical factors | Number of unfavorable factors | Event* | median survival (months) | log rank p | Event* risk HR (±95% CI) | P | ||
|---|---|---|---|---|---|---|---|---|---|
| absent n (%) | present n (%) | ||||||||
| Overall Survival (OS) | 0 | 3 (1.7) | 0 (0.0) | 94.33 | 1 (ref.) | ||||
| 1 | 29 (16.6) | 4 (4.7) | 91.77 | ||||||
| NR1/2 rs3732359 | AA | 2 | 43 (24.6) | 13 (15.1) | 91.31 | 3.02 (0.86–10.59) | 0.085 | ||
| SLC22A16 rs7756222 | CC | 3 | 61 (34.9) | 27 (31.4) | 86.51 | <0.00001 | 4.40 (1.33–14.49) | 0.015 | |
| SLC22A16 rs9487402 | TG/GG | 4 | 29 (16.6) | 22 (25.6) | 72.75 | 6.59 (1.97–22.02) | 0.002 | ||
| T [tumor; TNM] | >1 | 5 | 10 (5.7) | 16 (18.6) | 40.39 | 12.03 (3.50–41.40) | 0.00008 | ||
| N [nodes; TNM] | >0 | 6 | 0 (0.0) | 4 (4.7) | 21.26 | 10.88 (9.01–185.47) | <0.00001 | ||
| M [metastases; TNM] | yes | 0–2 | 75 (42.9) | 14 (16.9) | 92.18 | 1 (ref.) | |||
| 3–4 | 90 (51.4) | 49 (59.0) | 84.33 | <0.00001 | 2.36 (1.34–4.14) | 0.003 | |||
| 5–6 | 10 (5.7) | 20 (24.1) | 36.31 | 6.34 (3.27–12.30) | <0.00001 | ||||
| 0 | 28 (16.7) | 4 (4.5) | 89.82 | 1 (ref. | |||||
| 1 | 14 (8.3) | 9 (10.2) | 79.61 | 3.71 (1.14–12.06) | 0.029 | ||||
| Progression-Free | SLC22A16 rs7756222 | CC | 2 | 88 (52.4) | 44 (50.0) | 77.79 | 0.00007 | 3.20 (1.15–8.91) | 0.026 |
| Survival (PFS) | PGR rs1824125 | GG | 3 | 37 (22.0) | 31 (35.2) | 51.60 | 5.15 (1.82–14.60) | 0.002 | |
| PGR rs11224560 | CC | 4 | 1 (0.6) | 6 (6.8) | 16.03 | 19.18 (5.34–68.83) | <0.00001 | ||
| M [metastases; TNM] | yes | 0 | 28 (16.7) | 4 (4.3) | 89.82 | 1 (ref.) | |||
| 1–2 | 102 (60.7) | 53 (56.4) | 78.00 | 3.28 (1.19–9.06) | 0.022 | ||||
| 3 | 37 (22.0) | 31 (35.2) | 51.60 | 0.00003 | 5.15 (1.82–14.60) | 0.002 | |||
| 4 | 1 (0.6) | 6 (6.8) | 16.03 | 19.18 (5.34–68.83) | <0.00001 | ||||
| 0 | 77 (28.1) | 1 (7.7) | 81.26 | 1 (ref.) | |||||
| 1 | 63 (23.0) | 1 (7.7) | 81.69 | 1.34 (0.08–21.38) | 0.837 | ||||
| Recurrence-Free | DPYD rs291593 | CC | 2 | 83 (30.3) | 2 (15.4) | 88.69 | 0.00004 | 0.89 (0.05–14.29) | 0.937 |
| AKR1C3 rs3209896 | AG | 3 | 51 (18.6) | 9 (69.2) | 52.34 | 13.14 (1.64–105.14) | 0.015 | ||
| Survival (RFS) | PR status | negative | 0–2 | 223 (81.4) | 4 (30.8) | 83.93 | <0.00001 | 1 (ref.) | |
| 3 | 51 (18.6) | 9 (69.2) | 52.34 | 10.60 (3.26–34.44) | 0.00009 | ||||
HR- hazard ratio; 95%CI- confidence interval; bolded numbers indicate results with p < 0.05; *OS: death; PFS: progression; RFS: recurrence.